The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis.

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Future Science OA Pub Date : 2024-12-31 Epub Date: 2024-10-11 DOI:10.1080/20565623.2024.2409054
Shu-Yi Dong, Shuxin Ding, Zhen Meng, Bo Zou
{"title":"The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis.","authors":"Shu-Yi Dong, Shuxin Ding, Zhen Meng, Bo Zou","doi":"10.1080/20565623.2024.2409054","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the clinic-pathological features and prognostic value regarding PSMD14 in cancers.<b>Materials & methods:</b> Literature was gathered from public databases until 22 June 2023 to analyze data on survival rates and clinicopathological characteristics associated with PSMD14. TCGA and GEO data were also utilized for validation.<b>Results:</b> Eight reports on seven types of tumors showed that high PSMD14 expression was linked to poorer overall survival and disease-free survival. PSMD14 expression also correlated with larger tumor size, differentiation and metastasis, as well as the effectiveness of various chemotherapy drugs.<b>Conclusion:</b> PSMD14 could serve as a potential biomarker of poor prognosis in cancers, including lung cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer and hepatocellular carcinoma.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2409054"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486200/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2024.2409054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To evaluate the clinic-pathological features and prognostic value regarding PSMD14 in cancers.Materials & methods: Literature was gathered from public databases until 22 June 2023 to analyze data on survival rates and clinicopathological characteristics associated with PSMD14. TCGA and GEO data were also utilized for validation.Results: Eight reports on seven types of tumors showed that high PSMD14 expression was linked to poorer overall survival and disease-free survival. PSMD14 expression also correlated with larger tumor size, differentiation and metastasis, as well as the effectiveness of various chemotherapy drugs.Conclusion: PSMD14 could serve as a potential biomarker of poor prognosis in cancers, including lung cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer and hepatocellular carcinoma.

基于生物信息学和荟萃分析的 PSMD14 在癌症中的临床病理和预后意义。
目的:评估PSMD14在癌症中的临床病理特征和预后价值:从公共数据库中收集截至2023年6月22日的文献,分析与PSMD14相关的生存率和临床病理特征数据。此外,还利用 TCGA 和 GEO 数据进行验证:结果:关于七种类型肿瘤的八份报告显示,PSMD14的高表达与较差的总生存率和无病生存率有关。PSMD14的表达还与肿瘤体积增大、分化和转移以及各种化疗药物的疗效相关:结论:PSMD14可作为肺癌、头颈部鳞癌、卵巢癌、乳腺癌和肝细胞癌等癌症预后不良的潜在生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future Science OA
Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
5.00
自引率
4.00%
发文量
48
审稿时长
13 weeks
期刊介绍: Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信